Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners

INTRODUCTION: HIV-infected prisoners lose viral suppression within the 12 weeks after release to the community. This prospective study evaluates the use of buprenorphine/naloxone (BPN/NLX) as a method to reduce relapse to opioid use and sustain viral suppression among released HIV-infected prisoners...

Descripción completa

Detalles Bibliográficos
Autores principales: Springer, Sandra A., Qiu, Jingjun, Saber-Tehrani, Ali Shabahang, Altice, Frederick L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365007/
https://www.ncbi.nlm.nih.gov/pubmed/22719814
http://dx.doi.org/10.1371/journal.pone.0038335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365007/
https://www.ncbi.nlm.nih.gov/pubmed/22719814
http://dx.doi.org/10.1371/journal.pone.0038335

Ejemplares similares